Clinical Trials Logo

Clinical Trial Details — Status: Terminated

Administrative data

NCT number NCT02728700
Other study ID # IRB-34973
Secondary ID NCI-2016-00387PE
Status Terminated
Phase Phase 1
First received
Last updated
Start date February 2016
Est. completion date July 2018

Study information

Verified date August 2018
Source Stanford University
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This pilot phase I/II trial studies the side effects and how well sirolimus and mycophenolate mofetil work in preventing graft versus host disease (GvHD) in patients with hematologic malignancies undergoing hematopoietic stem cell transplant (HSCT). Biological therapies, such as sirolimus and mycophenolate mofetil, use substances made from living organisms that may stimulate or suppress the immune system in different ways and stop tumor cells from growing. Giving sirolimus and mycophenolate mofetil after hematopoietic stem cell transplant may be better in preventing graft-versus-host disease.


Description:

PRIMARY OBJECTIVES:

I. Evaluate the safety and feasibility of administering sirolimus and mycophenolate mofetil (MMF) as prophylaxis of grade III-IV acute graft versus host disease (aGvHD) in patients undergoing mismatched unrelated and related donor hematopoietic stem cell transplant (HSCT).

OUTLINE:

Patients receive sirolimus orally (PO) starting on day -3, 3 times a week during hospitalization and then once a week for up to 6 months. Patients undergo HSCT on day 0. Patients also receive mycophenolate mofetil intravenously (IV) or PO three times a day (TID) on days 1-180. Treatment continues in the absence of disease progression or unacceptable toxicity.

After completion of study treatment, patients are followed up at days 30, 60, 100, 180, 270, and 365, and then yearly thereafter.


Recruitment information / eligibility

Status Terminated
Enrollment 1
Est. completion date July 2018
Est. primary completion date April 2017
Accepts healthy volunteers No
Gender All
Age group 3 Years to 30 Years
Eligibility Inclusion Criteria:

- Subjects must have one of the following disease categories:

- Acute myeloid leukemia (AML) beyond 2nd remission or relapsed/refractory disease

- Acute lymphoblastic leukemia (ALL) beyond 2nd remission or relapsed/refractory disease

- Chronic myeloid leukemia (CML) beyond 2nd chronic phase or in blast crises

- Myelodysplastic syndrome (MDS)

- Myeloproliferative disorders including myeloid metaplasia and myelofibrosis

- High risk non-Hodgkin's lymphoma (NHL) in first remission

- Relapsed or refractory NHL

- Hodgkin's lymphoma (HL) beyond first remission

- Performance status by Karnofsky of >= 70% or Lansky > 70% for patients < 16 years of age

- Human leukocyte antigen (HLA) mismatched related or unrelated donor identified 8/10 or 9/10

- Willingness to take oral medications during the transplantation period

- Willingness and ability to sign a written informed consent (assent if applicable)

Exclusion Criteria:

- Prior myeloablative allogeneic or autologous HSCT

- Human immunodeficiency virus (HIV) infection

- Pregnant or lactating females

- Evidence of uncontrolled active infection

- Down syndrome

- Serum creatinine (CR) < 1.5mg/dl or 24 hour CR clearance < 50 ml/min

- Direct bilirubin > 2 x upper limit of normal (ULN)

- Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) > 2 x ULN

- Carbon monoxide diffusing capability test (DLCO) > 60% predicted and in children- room air oxygen saturation > 92%

- Left ventricular ejection fraction < 45% and in children-shortening fraction < 26%

- Fasting cholesterol > 300 mg/dl or triglycerides > 300 while on lipid lowering agents

- Patients who have received an investigational drug within 30 days of enrollment in study

- Patients with prior malignancies except basal cell carcinoma or treated carcinoma in-situ; cancer treated with curative intent > 5 years will be allowed; cancer treatment with curative intent =< 5 years will not be allowed

Study Design


Related Conditions & MeSH terms

  • Adult Hodgkin Lymphoma
  • Adult Myelodysplastic Syndrome
  • Blast Crisis
  • Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive
  • Childhood Chronic Myelogenous Leukemia, BCR-ABL1 Positive
  • Childhood Hodgkin Lymphoma
  • Childhood Myelodysplastic Syndrome
  • Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive
  • Hodgkin Disease
  • Leukemia
  • Leukemia, Lymphoid
  • Leukemia, Myelogenous, Chronic, BCR-ABL Positive
  • Leukemia, Myeloid
  • Leukemia, Myeloid, Acute
  • Leukemia, Myeloid, Chronic-Phase
  • Lymphoma
  • Lymphoma, Non-Hodgkin
  • Myelodysplastic Syndromes
  • Myelofibrosis
  • Precursor Cell Lymphoblastic Leukemia-Lymphoma
  • Preleukemia
  • Primary Myelofibrosis
  • Recurrent Adult Acute Lymphoblastic Leukemia
  • Recurrent Adult Acute Myeloid Leukemia
  • Recurrent Adult Non-Hodgkin Lymphoma
  • Recurrent Childhood Acute Lymphoblastic Leukemia
  • Recurrent Childhood Acute Myeloid Leukemia
  • Recurrent Childhood Non-Hodgkin Lymphoma
  • Recurrent Chronic Myelogenous Leukemia, BCR-ABL1 Positive
  • Refractory Chronic Myelogenous Leukemia, BCR-ABL1 Positive
  • Refractory Non-Hodgkin Lymphoma
  • Syndrome

Intervention

Procedure:
Allogeneic Hematopoietic Stem Cell Transplantation
Undergo HSCT
Other:
Laboratory Biomarker Analysis
Correlative studies
Drug:
Mycophenolate Mofetil
Given IV
Sirolimus
Given PO

Locations

Country Name City State
United States Stanford University, School of Medicine Palo Alto California

Sponsors (1)

Lead Sponsor Collaborator
Stanford University

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Incidence of acute GvHD grade 3 & 4, according to the Glucksberg staging criteria Statistical analysis results will be reported using summary tables, figures, and data listings. Continuous variables will be summarized using the mean, standard deviation, median, minimum, and maximum. Up to 60 days post-transplant
Primary Incidence of acute GvHD grade 3 & 4, according to the Glucksberg staging criteria Statistical analysis results will be reported using summary tables, figures, and data listings. Continuous variables will be summarized using the mean, standard deviation, median, minimum, and maximum. Up to 100 days post-transplant
Secondary Incidence of thrombotic microangiopathy defined according to the bone marrow transplant clinical trials network toxicity committee Defined as: red blood cell fragmentation and at least two schistocytes per high-power field on peripheral smear; concurrent increased serum lactate dehydrogenase measurement above institutional baseline; concurrent doubling of serum creatinine or 50% increase in creatinine clearance from baseline and/or neurological dysfunction without other explanations; and negative direct and indirect Coombs. Statistical analysis results will be reported using summary tables, figures, and data listings. Continuous variables will be summarized using the mean, standard deviation, median, minimum, and maximum. Up to 100 days
Secondary Incidence of venous-occlusive disease (VOD) using Modified Seattle Criteria Severe VOD will be considered a dose limiting toxicity. Statistical analysis results will be reported using summary tables, figures, and data listings. Continuous variables will be summarized using the mean, standard deviation, median, minimum, and maximum. Up to 100 days
Secondary Severity of mucositis determined by National Cancer Institute Common Terminology Criteria for Adverse Events version 4.03 Grade III and IV will be considered dose limiting toxicities. Statistical analysis results will be reported using summary tables, figures, and data listings. Categorical variables will be summarized by numbers and percentages of subjects in corresponding categories. Up to 100 days
Secondary Time to neutrophil engraftment defined as first of 3 consecutive days with the absolute neutrophil count is > 500/ul in the peripheral blood Statistical analysis results will be reported using summary tables, figures, and data listings. Continuous variables will be summarized using the mean, standard deviation, median, minimum, and maximum. Baseline to up to 100 days
Secondary Time to platelet engraftment defined as the first day of a minimum of three consecutive measurements on different days when platelet count > 50,000/mm^3 and patient is transfusion-independent for a minimum of 7 days Statistical analysis results will be reported using summary tables, figures, and data listings. Continuous variables will be summarized using the mean, standard deviation, median, minimum, and maximum. Baseline to up to 100 days
See also
  Status Clinical Trial Phase
Completed NCT02916979 - Myeloid-Derived Suppressor Cells and Checkpoint Immune Regulators' Expression in Allogeneic SCT Using FluBuATG Phase 1
Not yet recruiting NCT06345495 - High Dose Ruxolitinib and Allogeneic Stem Cell Transplantation in Myelofibrosis Patients With Splenomegaly Phase 2
Terminated NCT04866056 - Jaktinib and Azacitidine In Treating Patients With MDS With MF or MDS/MPN With MF. Phase 1/Phase 2
Completed NCT02784496 - Long-Term Side Effects of Ruxolitinib in Treating Patients With Myelofibrosis Phase 2
Completed NCT00069680 - Genetic Analysis of Gray Platelet Syndrome
Active, not recruiting NCT04097821 - Platform Study of Novel Ruxolitinib Combinations in Myelofibrosis Patients Phase 1/Phase 2
Active, not recruiting NCT03289910 - Topotecan Hydrochloride and Carboplatin With or Without Veliparib in Treating Advanced Myeloproliferative Disorders and Acute Myeloid Leukemia or Chronic Myelomonocytic Leukemia Phase 2
Completed NCT04666025 - SARS-CoV-2 Donor-Recipient Immunity Transfer
Not yet recruiting NCT06397313 - RVU120 in Patients With Intermediate or High-risk, Primary or Secondary Myelofibrosis Phase 2
Not yet recruiting NCT06024915 - A Study to Evaluate Drug-Drug Interaction of TQ05105 Tablets Phase 1
Terminated NCT02877082 - Tacrolimus, Bortezomib, & Thymoglobulin in Preventing Low Toxicity GVHD in Donor Blood Stem Cell Transplant Patients Phase 2
Completed NCT02910258 - Interferon-pegyle α2a Efficiency and Tolerance in Myelofibrosis
Completed NCT00975975 - Basiliximab #2: In-Vivo Activated T-Cell Depletion to Prevent Graft-Versus_Host Disease (GVHD) After Nonmyeloablative Allotransplantation for the Treatment of Blood Cancer Phase 2
Completed NCT00997386 - Reduced Intensity Allogeneic PBSCT to Treat Hematologic Malignancies and Hematopoietic Failure States Phase 2
Completed NCT00666549 - Research Tissue Bank
Terminated NCT00522990 - Study to Assess the Safety of Escalating Doses of AT9283, in Patients With Leukemias Phase 1/Phase 2
Terminated NCT00393380 - Study of Parathyroid Hormone Following Sequential Cord Blood Transplantation From an Unrelated Donor Phase 2
Completed NCT00606437 - Total Body Irradiation With Fludarabine Followed by Combined Umbilical Cord Blood (UCB) Transplants Phase 1
Active, not recruiting NCT03952039 - An Efficacy and Safety Study of Fedratinib Compared to Best Available Therapy in Subjects With DIPSS-intermediate or High-risk Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis, or Post-essential Thrombocythemia Myelofibrosis and Previously Treated With Ruxolitinib Phase 3
Not yet recruiting NCT04709458 - Safety and Early Efficacy Study of TBX-2400 in Patients With AML or Myelofibrosis Phase 1